Wogonin (Synonyms: オウゴニン)

Name: Wogonin
Brand: MedChemExpress
SKU: HY-N0400
Rating: 5.0 (24 reviews)

製品番号: HY-N0400 純度: 99.54%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 632-85-9

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$60	在庫あり	Estimated Time of Arrival: December 31
10 mg	$96	在庫あり	Estimated Time of Arrival: December 31
25 mg	$200	在庫あり	Estimated Time of Arrival: December 31
50 mg	$360	在庫あり	Estimated Time of Arrival: December 31
100 mg	$540	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 24 publication(s) in Google Scholar

Other Forms of Wogonin:

Wogonin (Standard) お問い合わせ

顧客検証

Cell Proliferation/Viability Assay

Flow Cytometry

RT-PCR

: Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]; Cells were treated with 0, 12.5, 25, or 50 μM Wogonin and examined for cell viability using cell counting kit (CCK)-8 assay.

: Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]; Western blot results suggested that MSC^IPFP-Exo and Wogonin-MSC^IPFP-Exo (25 μM) groups showed positive expression of the Exo-specific surface proteins CD81, CD63, and CD9, and negative expression of Calnexin.

: Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]; Wogonin (25 μM) treatment enhances the promotion of chondrocyte proliferation and inhibition of apoptosis by MSC^IPFP-Exo.

: Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]; Wogonin-MSC^IPFP-Exo (25 μM) suppresses interleukin (IL)-1β-triggered chondrocyte extracellular matrix (ECM) degradation. Chondrocytes were incubated with MSC^IPFP-Exo or Wogonin-MSC^IPFP-Exo in the presence or absence of IL-1β (10 ng/mL) for 24 hours.

: Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]; Quantification of Exo biogenesis-related gene expression (Rab27a, Rab7a, SNAP23, Rab5, ATG5, and ATG16L1) in MSC^IPFP with or without wogonin (25 μM) pretreatment, measured by quantitative real-time polymerase chain reaction (qRT-PCR).

: Wogonin purchased from MedChemExpress. Usage Cited in: J Immunol Res. 2020 Jun 1;2020:3032425. [Abstract]; Dose-dependent inhibition of STAT3 and ERK phosphorylation by Wogonin in LPS-treated B cells. CD19⁺ B cells were cultured with LPS for 6 h in the presence or absence of Wogonin (12.5, 25, and 50 μM) are analyzed and quantified by Western Blot.

CDK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

Wnt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

IC₅₀ & Target^[1]

CDK8

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	42.3 3 Compound: Wogonin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
A549	IC₅₀	15.8 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
A549	IC₅₀	20.1 3 Compound: 1	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
A549	IC₅₀	15.8 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
A549	IC₅₀	42.3 3 Compound: Wogonin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
A549	IC₅₀	20.1 3 Compound: 1	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
B16	IC₅₀	26.4 3 Compound: 1	Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
B16	IC₅₀	26.4 3 Compound: 1	Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
A549	IC₅₀	15.8 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
BV-2	IC₅₀	7.8 3 Compound: Wgn, Wogonin	Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs	[PMID: 22366656]
BV-2	IC₅₀	7.8 3 Compound: Wgn, Wogonin	Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs	[PMID: 22366656]
DLD-1	IC₅₀	36.87 3 Compound: 3; Wogonin	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
CHO	IC₅₀	>350 3 Compound: 4	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	[PMID: 12713409]
A549	IC₅₀	20.1 3 Compound: 1	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
A549	IC₅₀	42.3 3 Compound: Wogonin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HCT-116	IC₅₀	27.3 3 Compound: Wogonin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
DLD-1	IC₅₀	36.87 3 Compound: 3; Wogonin	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
B16	IC₅₀	26.4 3 Compound: 1	Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
HepG2	IC₅₀	17.6 3 Compound: Wogonin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HCT-116	IC₅₀	27.3 3 Compound: Wogonin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HepG2	IC₅₀	19 3 Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
HepG2	IC₅₀	37.89 3 Compound: 3; Wogonin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
BV-2	IC₅₀	7.8 3 Compound: Wgn, Wogonin	Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs	[PMID: 22366656]
HepG2	IC₅₀	19.5 3 Compound: 1	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
HepG2	IC₅₀	17.6 3 Compound: Wogonin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HepG2	IC₅₀	19 3 Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
HepG2	IC₅₀	37.89 3 Compound: 3; Wogonin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HepG2 2.2.15	IC₅₀	4 6 Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days	[PMID: 24549242]
CHO	IC₅₀	> 350 3 Compound: 4	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	[PMID: 12713409]
HepG2	IC₅₀	19.5 3 Compound: 1	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
DLD-1	IC₅₀	36.87 3 Compound: 3; Wogonin	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HT-29	IC₅₀	39.55 3 Compound: 3; Wogonin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HepG2 2.2.15	IC₅₀	4 6 Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days	[PMID: 24549242]
HCT-116	IC₅₀	27.3 3 Compound: Wogonin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HUVEC	IC₅₀	105 3 Compound: 3	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	[PMID: 9214730]
HT-29	IC₅₀	39.55 3 Compound: 3; Wogonin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HEK293	IC₅₀	28.1 3 Compound: 31	Anti-inflammatory activity against TNFalpha-induced HEK293 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay Anti-inflammatory activity against TNFalpha-induced HEK293 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay	[PMID: 37683361]
MCF7	IC₅₀	28 3 Compound: 1	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
HUVEC	IC₅₀	105 3 Compound: 3	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	[PMID: 9214730]
MCF7	IC₅₀	30 1 Compound: 44	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 36205223]
HT-29	IC₅₀	39.55 3 Compound: 3; Wogonin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
MCF7	IC₅₀	30 1 Compound: 44	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 36205223]
MCF7	IC₅₀	30 3 Compound: Wagonin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 32707525]
MCF7	IC₅₀	30 3 Compound: Wagonin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 32707525]
HUVEC	IC₅₀	105 3 Compound: 3	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	[PMID: 9214730]
HepG2	IC₅₀	17.6 3 Compound: Wogonin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
MCF7	IC₅₀	30 3 Compound: Wogonin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31300317]
MCF7	IC₅₀	30 3 Compound: Wogonin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31300317]
MV4-11	IC₅₀	30.7 3 Compound: Wogonin	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
MCF7	IC₅₀	30 3 Compound: Wogonin	Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition	[PMID: 34411892]
HepG2	IC₅₀	19 3 Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
HepG2	IC₅₀	19.5 3 Compound: 1	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
RAW264.7	IC₅₀	1.07 3 Compound: Wogonin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay	[PMID: 19233646]
MCF7	IC₅₀	28 3 Compound: 1	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
HepG2	IC₅₀	37.89 3 Compound: 3; Wogonin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
Sf21	IC₅₀	12.3 3 Compound: 22	Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis	[PMID: 30733087]
MV4-11	IC₅₀	30.7 3 Compound: Wogonin	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HepG2 2.2.15	IC₅₀	4 6 Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days	[PMID: 24549242]
Sf9	IC₅₀	190 1 Compound: 22	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy	[PMID: 30733087]
Sf9	IC₅₀	190 1 Compound: Wogonin	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b	[PMID: 31238183]
Sf9	IC₅₀	190 1 Compound: 22	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy	[PMID: 30733087]
Sf9	IC₅₀	190 1 Compound: Wogonin	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b	[PMID: 31238183]
MCF7	IC₅₀	28 3 Compound: 1	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
MCF7	IC₅₀	30 1 Compound: 44	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 36205223]
RAW264.7	IC₅₀	1.08 3 Compound: Wogonin	Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells	[PMID: 14980657]
SW480	IC₅₀	35.06 3 Compound: 3; Wogonin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
MCF7	IC₅₀	30 3 Compound: Wagonin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 32707525]
RAW264.7	IC₅₀	1.07 3 Compound: Wogonin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay	[PMID: 19233646]
Sf21	IC₅₀	12.3 3 Compound: 22	Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis	[PMID: 30733087]
MCF7	IC₅₀	30 3 Compound: Wogonin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31300317]
MCF7	IC₅₀	30 3 Compound: Wogonin	Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition	[PMID: 34411892]
SW1353	IC₅₀	39 3 Compound: 6	Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation	[PMID: 19555121]
SW480	IC₅₀	35.06 3 Compound: 3; Wogonin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
MCF7	IC₅₀	30 3 Compound: Wogonin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 37229829]
MV4-11	IC₅₀	30.7 3 Compound: Wogonin	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
RAW264.7	IC₅₀	1.07 3 Compound: Wogonin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay	[PMID: 19233646]
RAW264.7	IC₅₀	1.08 3 Compound: Wogonin	Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells	[PMID: 14980657]
SW1353	IC₅₀	39 3 Compound: 6	Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation	[PMID: 19555121]
SW480	IC₅₀	35.06 3 Compound: 3; Wogonin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
Sf21	IC₅₀	12.3 3 Compound: 22	Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis	[PMID: 30733087]
Sf9	IC₅₀	190 1 Compound: 22	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy	[PMID: 30733087]
Sf9	IC₅₀	190 1 Compound: Wogonin	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b	[PMID: 31238183]

体外実験

Wogonin (0-200 μM) exhibits a dose- and time- dependent reduces in cell viability of caco-2, SW1116 and HCT116 cells. Wogonin (10-40 μM) induces G1 phase arrest in HCT-116 cells. Wogonin also supresses Wnt signaling pathway in HCT116 cells. Wogonin interfers in the activity of transcription factor TCF/Lef family. Moreover, Wogonin inhibits β-catenin-mediated transcription through suppressing the activity of CDK8^[1]. Wogonin shows cytotoxic and antiproliferative effects on HeLa cells. Wogonin (90 μM) induces cell cycle arrest at G0-G1 phase, and suppresses the levels of cyclin D1 and Cdk4 markedly in HeLa cells^[2]. Wogonin (1.25, 2.5, 5, 10, 20 μg/ml) suppresses EtOH-induced inflammatory response in RAW264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Wogonin (30, 60 mg/kg) reduces tumor growth of HCT116 cells in a xenograft model^[1]. Wogonin (25, 50, 100 mg/kg) protects against liver injury and pathological characteristics of ALD in mice. Wogonin activates PPAR-γ expression in mice with ALD and EtOH induced RAW264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

284.26

分子式

C₁₆H₁₂O₅

CAS 番号

632-85-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5179 mL	17.5895 mL	35.1791 mL
5 mM	0.7036 mL	3.5179 mL	7.0358 mL
10 mM	0.3518 mL	1.7590 mL	3.5179 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (7.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 24 mg/mL (84.43 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.83%

Select Batch:

データシート (281 KB) SDS (394 KB)

COA (250 KB) HNMR (169 KB) LCMS (404 KB)

取扱説明書 (2659 KB)

参考文献

[1]. He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47. [Content Brief]

[2]. Yang L, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009 Dec;87(6):933-42. [Content Brief]

[3]. Li HD, et al. Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106. [Content Brief]

細胞実験 ^[1]	HCT116 cells are planted on a 96-well plate (1 × 10⁵ cells per well). Different concentrations of wogonin are added and incubated for 24 h. Subsequently, 20 μL of MTT solution (5 mg/mL) is transferred to each well and the plates are incubated for 4 h at 37°C and 5% CO₂. The supernatant is aspirated off and 100 μL DMSO is added to dissolve the formazan crystal. The mixture is shaken and measured at 570 nm using a universal microplate reader. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[3]	C57BL/6 mice, male, 6-8 weeks old, weighing 18-22 g mice are housed at comfortable environment and are acclimatized for 3 days before the experiment. A total of 48 mice are randomLy divided into six groups of 8 animals, respectively control diet (CD)-fed mice, EtOH-fed mice, wogonin-treated mice at the dose of 25, 50, 100 mg/kg/day and the positive (dexamethasone, 1 mg/kg/day)-treated mice. Modeling process has a total of 16 days including a liquid diet adaptation period for 3 days and modeling for 13 days. The EtOH-fed mice are fed containing 5% v/v ethanol liquid diets adding certain vitamin and choline for 16 days, and mice are gavaged with a single binge ethanol administration (5 g/kg, body weight, 20% ethanol) at last day. At the same time, the wogonin-treated mice and the positive-treated mice are not only plus the ethanol administration, but also plus the medicines by gavage daily, whereas the CD-fed mice are fed with control liquid diets and gavaged with isocaloric maltose-dextrin at last day. All diets are prepared fresh daily. 9 h after the last gavage alcohol, mice are sacrificed under anaesthesia, the liver tissues and blood are collected for further analysis. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47. [Content Brief] [2]. Yang L, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009 Dec;87(6):933-42. [Content Brief] [3]. Li HD, et al. Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5179 mL	17.5895 mL	35.1791 mL	87.9477 mL
	5 mM	0.7036 mL	3.5179 mL	7.0358 mL	17.5895 mL
	10 mM	0.3518 mL	1.7590 mL	3.5179 mL	8.7948 mL
	15 mM	0.2345 mL	1.1726 mL	2.3453 mL	5.8632 mL
	20 mM	0.1759 mL	0.8795 mL	1.7590 mL	4.3974 mL
	25 mM	0.1407 mL	0.7036 mL	1.4072 mL	3.5179 mL
	30 mM	0.1173 mL	0.5863 mL	1.1726 mL	2.9316 mL
	40 mM	0.0879 mL	0.4397 mL	0.8795 mL	2.1987 mL
	50 mM	0.0704 mL	0.3518 mL	0.7036 mL	1.7590 mL
	60 mM	0.0586 mL	0.2932 mL	0.5863 mL	1.4658 mL
	80 mM	0.0440 mL	0.2199 mL	0.4397 mL	1.0993 mL
	100 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8795 mL

Wogonin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Wogonin632-85-9CDKWntAutophagyApoptosisCyclin dependent kinaseInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Wogonin (Synonyms: オウゴニン)

カスタマーレビュー

Other Forms of Wogonin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

Wnt アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Wogonin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Wogonin (Synonyms: オウゴニン)

カスタマーレビュー

Other Forms of Wogonin:

Wogonin 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

Wnt アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Wogonin 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Wogonin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report